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Personalised mapping of tumour development in synchronous
colorectal cancer patients
Valentina Thomas 1,2, Maura B. Cotter3,4, Miriam Tosetto3,4, Yi Ling Khaw3,4, Robert Geraghty3,4, Desmond C. Winter3,4,
Elizabeth J. Ryan 3,4,5, Kieran Sheahan 3,4✉ and Simon J. Furney 1,2✉
Synchronous colorectal cancers (syCRCs) are two or more primary tumours identified simultaneously in a patient. Previous studies
report high inter-tumour heterogeneity between syCRCs, suggesting independent origin and different treatment response, making
their management particularly challenging, with no specific guidelines currently in place. Here, we performed in-depth
bioinformatic analyses of genomic and transcriptomic data of a total of eleven syCRCs and one metachronous CRC collected from
three patients. We found mixed microsatellite status between and within patients. Overlap of mutations between synchronous
tumours was consistently low (<0.5%) and heterogeneity of driver events across syCRCs was high in all patients. Microbial analysis
revealed the presence of Fusobacterium nucleatum species in patients with MSI tumours, while quantification of tumour immune
infiltration showed varying immune responses between syCRCs. Our results suggest high heterogeneity of syCRCs within patients
but find clinically actionable biomarkers that help predict responses to currently available targeted therapies. Our study highlights
the importance of personalised genome and transcriptome sequencing of all synchronous lesions to aid therapy decision and
improve management of syCRC patients.
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INTRODUCTION
Colorectal cancer (CRC) is the third most frequently diagnosed
malignancy and the fourth leading cause of cancer-related deaths
worldwide1. The main challenge in the treatment of this disease is
its high intra- and inter-tumour heterogeneity, which develops
through multiple genetic and epigenetic pathways of genome
instability, each contributing distinct features to the tumour
genome2–4. CRCs vary in their cancer-associated driver mutations,
which can be found in a number of genes, such as KRAS and
BRAF5. About 15% of CRCs acquire abnormalities in DNA mismatch
repair (MMR) genes, which lead to microsatellite instability (MSI)6,7.
MSI is typically mutually exclusive with chromosomal instability
(CIN), which accounts for the majority of lesions8,9. CRCs also vary
in their microbiome composition, with some enriched in
Fusobacterium nucleatum and decreasing in size after antibiotic
treatment10. Knowledge on the status of said features in a cancer
provides biomarkers that predict its response to targeted
therapies, such as KRAS wild type status for anti-EGFR therapy,
BRAF mutant status for combined BRAF and MEK inhibition
therapy, MSI status for immunotherapy, high CIN for VEGF-A
combination therapy, and Fusobacterium-load for antimicrobial
intervention10–21. However, as in the case of a subset of KRAS wild
type tumours that do not respond to anti-EGFR therapy22, not all
occurrences behave analogously, outlining the need for multiple
biomarkers to improve management. Recent research shows that
different molecular characteristics, prognosis and treatment out-
come of CRC also vary according to tumour sidedness22 and
tumour immune contexture23,24. Further efforts to advance
targeted intervention focused on subtyping CRCs based on gene
expression profiles and yielded two major classifiers: the
consensus molecular subtypes and the CRC intrinsic subtypes,
both of which hold significant potential for further diagnostic
value25,26.
About 4% of CRC patients develop multiple primary colorectal
tumours diagnosed simultaneously or within 6 months of each
other, known as synchronous CRCs (syCRCs)27,28. Predisposing
known genetic conditions are causative for about only 10% of
syCRCs27, suggesting that other genetic and environmental risk
factors are involved. Previous studies on syCRCs have reported
high heterogeneity of variants between synchronous tumours,
with distinct mutations occurring in known CRC genes, and
variation between tumour signature content, immune cell scores
and MSI status29–32. Although prognosis of syCRC patients does
not seem to vary significantly from that of solitary CRC
patients30,33, an understanding of the mechanisms implicated in
this phenomenon is still limited and no specific guidelines are
currently available for the management and treatment of
synchronous cases.
Here, we performed an in-depth characterisation of 12 tumours
from 3 syCRC patients (Table 1) by analysing histopathological,
whole-genome sequencing (WGS) and RNA-sequencing data. We
assessed the extent of genetic overlap between synchronous
tumours and examined associations between clinicopathological




A total of twelve tumour samples (11 primary and 1 metachro-
nous) were collected from three treatment naive sporadic (i.e.,
non-hereditary) CRC patients (Patient A, Patient B, and Patient C)
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and analysed in this study. Clinicopathologic data of patients are
provided in Table 1. The patients reported no family history of
CRC, and the majority of tumours were located on the right side of
the colon but span from the caecum to the sigmoid colon.
Patient A
Patient A was a 36-year-old male with a history of ulcerative colitis,
including numerous flare-ups over the preceding 2 years and had
been treated with Pentasa (mesalazine/5ASA). Background inac-
tive chronic colitis and low-grade dysplasia was identified in
almost every section on histological examination, suggesting a
field effect across the entire colon. The tumours were therefore
arising in a bed of inflammation rather than in normal mucosa.
Two primary tumours in the ascending colon were collected
(tumours A1 and A2). WGS revealed a higher mutation burden in
tumour A1 compared with A2, for all mutation types (Supple-
mentary Table 1). The majority of mutations found in patient A
were unique to either A1 or A2 (Fig. 1a and Supplementary Fig. 1a,
b). Distinct TP53 driver mutations were found in both tumours.
Additional mutations in SMAD4 and MYC occurred in A1, while
none of the overlapping mutations were identified as a known
driver (Fig. 1b). This suggests that syCRCs in patient A are
genetically distinct and likely to have originated independently.
We performed mutational signature analysis (https://cancer.
sanger.ac.uk/cosmic/signatures_v2) to investigate the mutational
processes that occurred during tumour development. This analysis
revealed similar signature profiles in A1 and A2, with a significant
proportion of the age-related signature 1. (Fig. 1c and Supple-
mentary Fig. 1c). No MMR-deficiency related signature was found.
Copy number alteration (CNA) analysis revealed high CIN in both
tumours and tumour A1 appeared to exhibit hyperdiploidy (Fig.
1d and Supplementary Fig. 1d). EGFR was amplified in both lesions
and the amplification of other known CRC oncogenes, such as
KRAS and TOP1, was exclusive to either A1 or A2. Similarly, TP53
was found to be deleted in A2 but amplified in A1, further
highlighting heterogeneity of these tumours (Fig. 1e).
DNA analysis of gut microbial organisms in patient A revealed
high abundance of Bacteroidetes and Firmicutes spp. (Fig. 1f).
Transcriptomic subtyping predicted both tumours as CMS4 and
CRIS-B (Supplementary Table 1). A1 displayed lower abundance of
neutrophils but greater amounts of B cells and CD8+ T cells,
whereas CD4+ T cells were only detected in A2, which showed
higher neutrophil-to-lymphocyte ratio and higher CD4/CD8 ratio,
both linked to poor clinical outcomes (Fig. 1g).
Patient B
Patient B was a 79-year-old female presenting with five primary
synchronous tumours ranging from the caecum to the sigmoid
colon (tumours B1–B5; Table 1). Higher single-nucleotide variant
(SNV) and InDel burdens were found in tumours B1–B4 compared
with B5, which, in turn, showed the highest number of structural
variants (SVs; Supplementary Table 1). Most mutations found in
patient B were unique to each primary tumour (Fig. 2a and
Supplementary Fig. 2a, b). However, the same BRAF V600E driver
mutation was identified in all MSI tumours B1–B4. Tumour B2 further
experienced a deletion in the MSH3 and MSH6 genes, whereas
tumours B1 and B4 showed an MSH6 insertion, with tumour B1
acquiring further mutations in PIK3CA H1047R and FBXW7 R385C
and tumour B4 developing mutations in FBXW7 G587fs, PMS1 F544fs
and TP53 L257P. Mutations in PIK3CA H1047R and FBXW7 G587fs
were also found in B3. B5 (MSS tumour) shared one APC E1554fs
mutation with B1, but no mutations with the rest of the primaries,
presenting distinct ones: FBXW7 R399* and KRAS G12D (Fig. 2b, c).
Driver SNV heterogeneity in the five tumours was corroborated by
mutation calling analysis of the RNA-seq data.
Mutational signature analysis showed tumours B1–B4 with a high
proportion of MMR-deficiency-related signatures, and absence of
these signatures in B5 (Fig. 2d and Supplementary Fig. 2c). This was
corroborated by protein immunohistochemistry (IHC), which showed
loss of MLH1 in tumours B1–B4 and reduction in MLH1 transcript
expression (Fig. 2e), likely due to hypermethylation of the MLH1
promoter. CNA analysis revealed low CIN in MSI tumours (B1–B4) and
high CIN in the MSS tumour B5 (Fig. 2f and Supplementary Fig. 2d).
B5 was the only sample to show EGFR amplification, KRAS was
amplified in B3 and B5 while tumour suppressor genes, such as DCC
and SMAD4, were deleted in B4 and B5 (Fig. 2g).
DNA analysis of gut microbial organisms associated with each
tumour within patient B revealed prevalence of Bacteroidetes and
Firmicutes spp., and evidence of F. nucleatum in all lesions (Fig. 2h).
Interestingly, tumours B1 and B5 were both categorised as CMS2
and CRIS-E. These are in concordance with the high CIN and KRAS
mutant state of B5 but not of B1. As expected, B2, B3 and B4 were
assigned to the MSI-like and BRAF-mutated CRIS-A. B4 was also
identified as CMS3 (Supplementary Table 1). The MSS B5 tumour
Table 1. Clinicopathologic data of patients.
Patient A B C
Gender Male Female Male



















Tumours A1 (MSS) B1 (MSI) C1 (MSI)
A2 (MSS) B2 (MSI) C2 (MSI)
B3 (MSI) C3 (MSI)
B4 (MSI) C4 (MSI)

















Stage pT4aN2b (A1) pT3N1 (B1) pT4 N0 (C1)
pT4bN2b (A2) pT3N1 (B2) pT2 N0 (C2)
pT3N1 (B3) pT3 N0 (C3)
pT3N1 (B4) pT2 N0 (C4)
pT3N1 (B5) pT3 N0 (C5)
Differentiation Poor (A1) Moderate (B1) Moderate (C1)
Poor (A2) Moderate (B2) Moderate (C2)
Moderate (B3) Moderate (C3)
Moderate (B4) Moderate (C4)
Moderate (B5) Poor (C5)
Mucinous
component
<10% (A1) 0% (B1) 0% (C1)
0% (A2) 40% (B2) 30% (C2)
60% (B3) 60% (C3)
70% (B4) 70% (C4)
10% (B5) 0% (C5)
A total of 12 tumours (11 primary and 1 metachronous) from 3 patients
were analysed.
V. Thomas et al.
2













showed an immune infiltration of ~15%, while infiltration in MSI
tumours ranged from ~11% in B1 to ~25% in B2. Together with
the lowest infiltration, B1 showed a lower abundance of
neutrophils, a higher fraction of CD8+ T cells and a lack of CD4+
T cells. The highest neutrophil-to-lymphocyte ratio was seen in B5,
followed by B4, B2, B3 and B1 (Fig. 2i).
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Fig. 1 Genomic and transcriptomic analyses for patient A. a A Venn diagram of SNVs shows 0.49% overlap between tumours. b Variant
Allele Frequencies (VAFs) of putative driver mutations show heterogeneous drivers in A1 and A2. c Mutational signature analysis. d Genomic
landscape of CNAs shows CIN in both A1 (ploidy of 3.58) and A2 (ploidy of 2.2). e Log-ratio of putative driver CNAs highlights heterogeneity of
tumourigenic events between A1 and A2. fMicrobial analysis of DNA data shows microbial abundance at the phylum level. g Quantification of
tumour immune infiltration for eight immune cell populations across A1 and A2.
V. Thomas et al.
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Fig. 2 Genomic and transcriptomic analyses for patient B. a Venn diagrams of SNVs for all lesions B1–B5 (left) and for MSI lesions B1–B4
(right) show low overlap between tumours. b Putative phylogenetic tree based on driver mutations. c VAFs of putative driver mutations.
d Mutational signature analysis. e Transcript counts of the MLH1 detected by RNA-seq analysis. f Genomic landscape of CNAs shows low CIN
for MSI samples B1 (ploidy: 2), B2 (ploidy: 1.95), B3 (ploidy: 2) and B4 (ploidy: 1.98), and higher CIN for MSS sample B5 (ploidy: 2.13). g Median
log-ratio of putative driver CNAs highlights heterogeneity of tumourigenic events between all lesions. h Microbial analysis of DNA data shows
microbial abundance at the phylum level. i Quantification of tumour immune infiltration reveals distinct profiles for eight immune cell
populations across B1–B5.
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Patient C
Patient C was a 70-year-old male who presented initially with four
primary synchronous tumours (C1–C4), and with a metachronous
tumour (C5) more than 6 months later. WGS revealed similar
burdens of SNVs, InDels and SVs in all tumour samples in patient C
(Supplementary Table 1). Most mutations occurred exclusively in
each lesion (Fig. 3a and Supplementary Fig. 3a, b). The same BRAF
V600E mutation occurred in all tumours, identifying it as a likely
early event in tumour development (Supplementary Fig. 3c).
Tumours C1 and C5 further acquired an insertion in the MSH6
gene, with tumour C1 acquiring mutations in PIK3CA H1047R, TP53
Q144* and TP53 R282W, and tumour C5 developing a mutation in
FBXW7 R385C. In contrast, tumours C2 and C4 experienced a
deletion in the MSH6 gene, with tumour C2 acquiring additional
mutations in APC R876* and tumour C4 gaining mutations in APC
E1554fs, PIK3CA Q546R and TP53 K382fs. C3 experienced a
deletion in MSH3 and acquired a mutation in POLH R253C (Fig.
3b, c and Supplementary Fig. 3d). Driver SNV heterogeneity was
corroborated by analysis of the RNA-seq data. Mutational
signature analysis unveiled high proportions of MMR-deficiency
related signatures in all tumours (Fig. 3d and Supplementary Fig.
3e). This was corroborated by loss of MLH1 expression detected by
IHC and reduction in MLH1 transcript expression (Fig. 3e) in all
tumours. CNA analysis reported low CIN in all tumours in patient C
(Fig. 3f and Supplementary Fig. 3f). We identified amplified
oncogenes, such as KRAS in C1 and MYC in C3–C5, and deleted
tumour suppressor genes, such as DCC in C5 (Fig. 3g).
DNA analysis of gut microbial organisms associated with each
tumour revealed prevalence of Bacteroidetes and Firmicutes spp.
across all lesions. DNA evidence of F. nucleatum was found in all
tumours C1–C5 (Fig. 3h). C1 was classified as CMS4 and CRIS-D.
CRIS-D was also assigned to C3, where an amplification of IGF2
was observed. C2 was classified as CMS2 and CRIS-E, in accordance
with an amplification of chromosome 13. C4 and C5 were assigned
to CRIS-C, in agreement with gains in chromosomes 8 (which
contains the proto-oncogene MYC) and, for C5, gains in
chromosomes 7 (which contains the EGFR gene) and 13
(Supplementary Table 1). The lowest immune infiltration (9.7%)
was observed in C5, while it increased to ~15% in C1 and C2, 26%
in C3 and 31% in C4. C3 and C4 showed a greater fraction of
classically activated M1 macrophages and a lack of tumour
promoter M2 macrophages. C3 showed greater abundance of B
cells, low abundance of T cells and a lack of neutrophils. Lower
CD4/CD8 ratios were seen in C4 and C5 (Fig. 3i).
DISCUSSION
Increasing numbers of syCRCs are identified as early diagnosis
technologies improve. syCRCs have distinguishing features to
solitary CRCs, with currently no specific guidelines to their
management27,28. As a rule, the tumour with the highest TNM
stage is utilised as a guide for prognosis and clinical management,
with lymph node positivity as the most important parameter. The
whole-genome analysis of syCRCs in this study highlights how
each patient represents a completely distinct scenario. Overall, our
results show a high degree of genetic heterogeneity between
syCRCs. Synchronous lesions within a patient harbour mainly
distinct mutations in the same known CRC genes, although
overlaps of few known driver mutations, such as BRAF V600E, did
occur. Indeed, the presence of the same BRAF V600E mutation in
all tumours in patient C is an interesting finding, in particular as
the mutation also occurs in the metachronous tumour C5. BRAF
mutation in the setting of MSI is strongly associated with sporadic
CRC. In patient C, this shared mutation could either suggest a
common tumour origin or is a striking example of convergent
evolution in tumour development, likely arising via the serrated
BRAF pathway from sessile serrated polyp precursors. However,
overall our results suggest syCRCs have a tendency to originate
independently, while often accessing the same mutational
processes29,30,32. In terms of the temporal development of the
tumours, for the older patients B (79 years of age) and C (70 years
of age) there are no records of prior endoscopy or biopsies prior to
the index admission. Therefore, the tumours in these patients may
have formed at various time points over the years. Patient A had a
longstanding history of ulcerative colitis and was enrolled in a
programme of routine endoscopic evaluation for surveillance of
dysplasia. The finding of dysplasia in patients with ulcerative
colitis is a known predictor of risk of subsequent development of
CRC and the tumours are likely to have developed synchronously.
DNA analysis of gut microbial organisms showed that the
distribution of Fusobacteria is in concordance with previous
observations reporting an increased abundance of F. nucleatum
in BRAF mutant, hypermutated, MSI tumours10. Analysis of the
microbiome associated with each tumour in patient A revealed
reduced diversity of the gut microbiota, which could be reflective
of a dysbiosis related to the patient’s history of ulcerative colitis34,
although these results could have been influenced by the
administration of an antibiotic bowel preparation in this case. A
previous study has shown differences in immune cell scoring
between synchronous tumour pairs29. Immune score quantifica-
tion has been validated as a prognostic marker of risk of
recurrence in colon cancer, with the quality and density of the
immune infiltrate affected by factors including the pre-existing
tumour microenvironment, the tumour genetics and the gut
microbiome35. Our findings reveal differences in microbial and
immune composition between synchronous tumours, further
highlighting the complexity inherent in these tumours. In
addition, recent findings have suggested that patients with
Fusobacterium-positive tumours could benefit from the adminis-
tration of antibiotics10, although research into the efficacy of
microbial-targeted treatments is still in its early stages.
Transcriptomic-based CRC molecular subtyping has revealed
clinical and prognostic associations of CRC subtypes25. We show
heterogeneity in molecular subtype classification of synchronous
tumours in two out of three patients. Transcriptome analysis
assigned both of Patient A’s tumours to the same molecular
subtype (CMS4/CRIS-B). Relevant shared features between CMS4
and CRIS-B include high CIN, TGF-β activation and epithelial-to-
mesenchymal transition (EMT), and are associated with poorly and
de-differentiated tumours with a stromal-mesenchymal pheno-
type. This TGF-β/EMT immune phenotype is consistent with the
patient’s history of ulcerative colitis. In addition, the shared
molecular subtype of A1 and A2 is not unexpected, as
histopathological review of the whole colon showed background
low-grade dysplasia. However, tumours in patients B and C fell
into different subtypes, highlighting the heterogeneity in these
patients. Of the nine MSI tumours included in this study, only one,
C5, was assigned to the CMS1 group, proposed as the ‘MSI-
immune’ group25. Tumour C5 was the metachronous primary
(occurred >6 months later) and the only poorly differentiated MSI
tumour (60% solid growth; Table 1), potentially contributing to the
inter-tumour transcriptomic heterogeneity in this patient. A
further three of the MSI tumours (B2, B3 and B4) were classified
as CRIS-A: the sub-group proposed to include MSI tumours26. This
highlights the difficulty of applying very defined classification
systems to individual tumours with different driver mutations and
genomic alterations. As immunotherapy is currently only recom-
mended for MSI-H deficient MMR tumours36, deeper investigation
into how the transcriptional patterns in syCRC MSI tumours
correspond to response to immunotherapy is warranted.
Overall, we found variation in common biomarkers, such as
BRAF and KRAS, for targeted therapies21 and also in other features
that might impact or predict treatment response20. In Patient A’s
tumours (both MSS), the KRAS wild type status and increase in
EGFR copy number make them candidates for treatment with the
V. Thomas et al.
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C1 C2 C3 C4 C5
Fig. 3 Genomic and transcriptomic analyses for patient C. a Venn diagram of SNVs shows low overlap between tumours. b Putative
phylogenetic tree based on driver mutations. c VAFs of putative driver mutations. d Mutational signature analysis. e Transcript counts of the
MLH1 detected by RNA-seq analysis. f Genomic landscape of CNAs shows low CIN for all samples C1 (ploidy: 2.03), C2 (ploidy: 2.06), C3 (ploidy:
2.13), C4 (ploidy: 2.02) and C5 (ploidy: 2.13). g Median log-ratio of putative driver CNAs highlights heterogeneity of tumourigenic events
between all lesions. h Microbial analysis of DNA data shows microbial abundance at the phylum level. i Quantification of tumour immune
infiltration reveals varying fractions for eight immune cell populations across all samples.
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anti-EGFR therapy Cetuximab37,38 if they should recur. The CMS4
and CRIS-B classifications for these tumours predict worse relapse-
free and overall survival for this patient. In Patient B, the MSI
samples B1–B4 show potential to respond to immunotherapy,
while this option would most likely have no effect on the MSS B5
cancer, in which, although we see an amplification of EGFR, we
also find a KRAS mutation which therefore excludes anti-EGFR
therapy as a treatment option39. CRIS-A is associated with a lack of
response to anti-EGFR therapy, which agrees with the normal copy
state of EGFR in B2, B3 and B4. Anti-metabolic therapies have been
suggested for CRIS-A subgroups26. In Patient C, all five tumours
show potential to benefit from similar treatments, namely BRAF
inhibition and, especially in the case of C3 and C4, immunother-
apy. The specific role of BRAF inhibition in MSI CRC, however,
remains to be determined21. CRIS-C is associated with Cetuximab-
sensitive tumours, proposing this therapy as a viable option for C4
and C5, while CRIS-E predicts poor response to anti-EGFR
treatment in C2.
In conclusion, to the best of our knowledge, we have conducted
the first WGS study of syCRCs. This has allowed us much broader
analytic resolution outside the exome in terms of identifying
shared/private mutations in each tumour, and the ability to
determine microbial composition in the tumour and matched
normal samples. In addition we have been able to conduct
analysis of structural variation, and show the SV heterogeneity in
patients’ tumours. Furthermore, we have conducted matched
RNA-seq analysis of multiple syCRCs. This has facilitated both CRC
consensus molecular subtyping and immune composition
analysis.
Previous studies have, in all but a few patient cases, conducted
exome analyses of paired synchronous tumours from patients. In
two of our patient case studies we have analysed five tumours
from each patient to construct a much richer depiction of the
overall genomic and transcriptomic heterogeneity in multiple
syCRCs. While our findings may not have impacted on the
standard of care treatment for these patients, compared with
previous studies we have identified heterogeneity in current and
emerging CRC biomarkers, which may have to be factored into
clinical decision-making for patients in the future.
In summary, our study highlights heterogeneity in genomic,
transcriptomic, microbial and immune CRC biomarkers in syCRC
patients, which could have strong implications for therapeutic
management, and requires thorough and careful examination.
METHODS
Clinical samples
Twelve tumour samples were collected from three treatment naive
sporadic CRC patients (Patient A, Patient B and Patient C) at St. Vincent’s
University Hospital (SVUH) in Dublin. Fresh tumour and normal tissue were
obtained from surgical resection specimens, with normal tissue blocks
taken some distance from the invasive tumours. Klean Prep (which
includes macrogol) was administered as a routine pre-operative bowel
preparation in two of three cases (patients A and B). Patient C did not have
bowel prep as was operated on as an emergency due to bowel
obstruction. Antibiotic bowel preparation was administered in one (patient
A, ciprofloxacin and metronidazole) along with pre-operative hydrocorti-
sone. In each case, the tumours were subjected to the SVUH routine
screening protocol for MSI testing. Based on the screening protocol the
clinician decides whether to request germline testing or not. In each case
germline testing was determined not necessary based on immunohisto-
chemical MSI and BRAF (real time PCR) results in conjunction with clinical
history. Adjacent healthy tissue, subjected to pathological quality control,
was additionally sampled from each patient to provide a reference of the
patient’s normal genome. Written informed patient consent was obtained
by the Centre for Colorectal Disease in SVUH and the study was approved
by the SVUH Research Ethics Committee. Tumours were classified
according to latest American Joint Committee on Cancer (AJCC) TNM
system (AJCC 8th Edition: Colorectal Cancer). All samples were stored at
−80 °C. Clinicopathological data were available for all patients and are
provided in Table 1.
MSI was assessed using IHC for MMR proteins, MLH1 (BD Bioscience,
clone G168-728), PMS2 (BD Biosciences, clone A16-4), MSH2 (Calbiochem,
clone FE11) and MSH6 (BD Biosciences, clone 44). IHC was performed on
the automated Leica BOND immunostainer.
DNA and RNA extraction
DNA and RNA extraction from frozen tissue samples was performed at
SVUH Dublin.
DNA. About 30mg (2 mm3) of frozen tissue was placed into a screw cap
vial preloaded with 1.4 mm ceramic beads (Cambio) and samples were
homogenised using the Precellys 24 tissue homogeniser (Bertin Instru-
ments) for 20 s at 5500 rpm. Subsequently, samples were incubated at
55 °C in a water bath for 2 h, vortexing the samples every 20min. DNA
isolation was carried out with the E.Z.N.A.® Tissue DNA Kit (Omega Bio-Tek)
as per the manufacturer’s protocol. Purity was assessed using the
NanoDrop noting the A260/280 > 1.8. Samples were run on an agarose gel
1% to check for degradation and RNA contamination. Fluorimetric
quantification was performed with the Qubit dsDNA HS assay kit
(Invitrogen).
RNA. About 30mg (2 mm3) of frozen tissue was placed into chilled
prefilled tubes with beads (Precellys® Ceramic kit 2.8 mm, reinforced) with
1ml of lysis buffer. Samples were homogenised at 4 °C using the Precellys
24 at 5500 rpm, 10 s ×2. RNA isolation from snap frozen tissue samples was
carried out with the E.Z.N.A.® Total RNA kit I (Omega Bio-Tek). RNA purity
was assessed using the NanoDrop noting the A260/280 > 2. Samples were
then run on the Bioanalyzer 2100 (Agilent) and only samples with RNA
integrity number > 7 were used for sequencing.
Whole-genome sequencing
For each patient, all synchronous tumours and a matched normal tissue
sample were selected for WGS. Paired end sequencing reads (151 bp) were
generated using Illumina HiSeq X sequencing technology, yielding ~×60
coverage per sample. Sequences were aligned to the human reference
genome (GRCh37/ hg19) using BWA40. PCR duplicates were marked using
Picard Tools (http://broadinstitute.github.io/picard) and InDel realignment
and base quality recalibration were conducted with the Genome Analysis
Toolkit (GATK) v3 (http://www.broadinstitute.org/gatk).
RNA-sequencing
RNA was isolated from all tumours in each patient and subjected to RNA-
sequencing analysis. Sequenced reads were aligned to the human
reference genome (GRCh37) using STAR41. SNP calling was conducted




Somatic mutations were identified by comparing each tumour sample with
adjacent healthy colorectal tissue as a matched normal.
Substitutions
SNVs were identified with mutation calling algorithms MuTect v142 and
Strelka v143. We used BEDTools44 to intersect their outputs, and only
retained mutations found by both callers. These were further intersected
with the dbSNP list of common variants (https://www.ncbi.nlm.nih.gov/
SNP/) to exclude potential germline variations. To ensure that no cancer-
associated variations were removed, mutations reported in the COSMIC
database (https://cancer.sanger.ac.uk/cosmic) were previously excluded
from the dbSNP list.
We calculated the variant allele frequency (VAF) of each SNV and further
validated mutations by only keeping the ones that met the following
parameters: normal alternate allele ≤ 1, minimum combined depth= 20,
minimum alternate depth= 2 and minimum VAF= 0.05.
V. Thomas et al.
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InDels
InDels were identified with Strelka v143 and filtered from potentially
germline variants in the same way as the substitutions (see above).
Structural variants
SVs (deletions, tandem duplications, inversions, translocations) were
identified using DELLY v0.7.945.
Copy number alterations
CNAs were identified using the R package FACETS v0.5.1446 and visualised
with the R package copy number v1.24.047.
Gene annotation and driver analysis
The genic location and functional impact of SNVs, InDels and SVs was
annotated using the Ensembl Variant Effect Predictor (VEP) v9748. Known
driver genes together with MMR and HR genes were searched for causative
mutations in all samples. This was done through the Cancer Genome
Interpreter49 https://www.cancergenomeinterpreter.org/home and VEP48.
The VAF of each identified driver was calculated to establish its prevalence.
CNAs were annotated using the annotate_variation function implemented
by ANNOVAR v2018Apr1650 and searched for drivers based on known CRC-
associated somatic gene CNAs51. The relevance of each putative driver
CNA was estimated through its median log-ratio, which was provided by
the FACETS analysis.
Mutations overlap with Venn diagrams
The overlap of SNVs, InDels and SVs between the tumours within a patient
was calculated and visualised with Venn diagrams using the R package
VennDiagram v1.6.2052.
Mutational signature analysis
Mutational signature analysis was performed to inform on the exposures
and biological history of a cancer. Mutational signatures were identified
from SNVs using the R package deconstructSigs v1.853 based on the pan-
cancer catalogue of 30 signatures referenced in the COSMIC database
(https://cancer.sanger.ac.uk/cosmic/signatures).
Gut microbiome analysis
Tumour and normal tissue-associated gut microbiota were identified from
DNA data using PathSeq v2.054, available from the GATK v4 (http://www.
broadinstitute.org/software/pathseq/).
RNA-seq data: quantification of gene expression, normalisation
and gene ID conversion
Gene counts of tumour samples were generated from RNA-seq data using
Kallisto55. Normalisation of RNA counts was performed with DESeq2
v1.2456, using rlog and the ‘~patient_id’ formula. Ensembl gene IDs were
mapped to Entrez and Symbol IDs using biomaRt v2.4057.
Molecular subtyping and tumour immune infiltration
Molecular subtyping of tumours based on gene expression profiles was
performed using two R implemented classification systems: the CMS
classifier v125, and the CRIS classifier v126.
Tumour immune contexture was analysed for each sample applying the
quanTIseq computational pipeline58, which uses RNA-seq data to quantify
the fractions of ten immune cell types (B cells, classically activated
macrophages M1, alternatively activated macrophages M2, neutrophils,
natural killer cells, CD4+ T cells, CD8+ T cells, regulatory T cells, monocytes
and dendritic cells) in heterogeneous tissues.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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